Drugs for Miyoshi Muscular Dystrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 8)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Glucosamine |
Approved, Investigational |
Phase 3 |
|
3416-24-8 |
439213 |
Synonyms:
(+)-2-amino-2-Deoxy-D-glucopyranose
(2R,3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol
(2S,5R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol
(3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol
(3R,4R,5S,6R)-3-amino-6-(Hydroxymethyl)oxane-2,4,5-triol
14257-69-3
2 amino 2 Deoxyglucose
2351-15-7
28905-10-4
2-Amino-2-deoxy-beta-D-glucopyranose
2-amino-2-deoxy-D-glucopyranose
2-amino-2-Deoxy-D-glucopyranose
2-amino-2-deoxy-D-glucose
2-amino-2-Deoxy-D-glucose
2-Amino-2-deoxy-D-glucose
2-amino-2-deoxyglucose
2-amino-2-Deoxyglucose
2-Aminoglucose
2B4D44B2-D5AC-4DA4-9BE6-A4AE9574E4A6
2-Deoxy-2-amino-D-glucose
2-Deoxy-2-aminoglucose
3416-24-8
4-04-00-02017 (Beilstein Handbook Reference)
58267-75-7
58-87-7
6490-70-6
880765-44-6
90-77-7
911653-84-4
AC1L2D1C
AC1L96WB
AC1L9B8P
AC1Q4UBH
beta-D-Glucosamine
bmse000247
BRN 1724602
BSPBio_002086
C00329
C08349
CHEBI:28393
CHEBI:47977
CHEMBL234432
chitosamine
Chitosamine
CID18897
CID439213
CID441477
Cosamin
CPD0-1193
D-(+)-Glucosamine
D04334
DB01296
|
D-glucosamine
D-Glucosamine
DivK1c_000261
Dona
Dona S
EINECS 222-311-2
Fides ecopharma brand OF glucosamine sulfate
GCS
Glucosamina
Glucosamina [INN-Spanish]
glucosamine
Glucosamine
Glucosamine (USAN/INN)
Glucosamine [USAN:INN]
Glucosamine sulfate
Glucosaminum
Glucosaminum [INN-Latin]
Hespercorbin
HMS500N03
HSDB 7469
IDI1_000261
InChI=1/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3-,4-,5-,6-/m1/s1
KBio1_000261
KBio2_001311
KBio2_003879
KBio2_006447
KBio3_001306
KBioGR_000970
KBioSS_001311
LS-71671
MolPort-002-507-091
MolPort-003-944-937
NCGC00164421-01
NCGC00178826-01
nchembio.189-comp4
nchembio.2007.41-comp7
nchembio.412-comp5
NINDS_000261
Opfermann brand OF glucosamine sulfate
partially N-deacetylated poly-beta-1,6-N-acetyl-D-glucosamine
Rottapharm brand OF glucosamine sulfate
SPBio_000477
Spectrum_000831
Spectrum2_000519
Spectrum3_000443
Spectrum4_000565
Spectrum5_000756
STK801823
Sulfate, glucosamine
Viartril-S
Xicil
|
|
2 |
|
Azacitidine |
Approved, Investigational |
Phase 2 |
|
320-67-2 |
9444 |
Synonyms:
2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one
320-67-2
4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
4-amino-1-b-D-Ribofuranosyl-S-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one
4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one
4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
4-amino-1-beta-D-Ribofuranosyl-S-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one
4-amino-1-β-D-ribofuranosyl-S-triazin-2(1H)-one
5 Azacytidine
5 AZC
5-AC
5AzaC
5-AZAC
5-azacitidine
5-aza-CR
5-azacytidine
5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine
5-AZCR
A 2385
A1287_SIGMA
A2385_SIGMA
AC1L1T1Y
Antibiotic U 18496
Azacitidina
Azacitidina [INN-Spanish]
Azacitidine
Azacitidine (JAN/USAN/INN)
Azacitidine [USAN:INN]
Azacitidinum
Azacitidinum [INN-Latin]
Azacytidine
BCBcMAP01_000083
BRN 0620461
BSPBio_003157
C11262
CCRIS 60
CHEBI:2038
CHEMBL1489
CID9444
cMAP_000082
CPD000857239
D001374
D03021
DB00928
DivK1c_000125
EINECS 206-280-2
EU-0100035
FT-0081170
HMS1921J22
HMS2092D08
HMS500G07
HSDB 6879
IDI1_000125
InChI=1/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1
|
Jsp005945
KBio1_000125
KBio2_001742
KBio2_002556
KBio2_004310
KBio2_005124
KBio2_006878
KBio2_007692
KBio3_002657
KBio3_003034
KBioGR_001444
KBioGR_002556
KBioSS_001742
KBioSS_002565
Ladakamycin
Lopac0_000035
LS-1189
MLS001333121
MLS001333122
MLS002153249
MolMap_000062
mylo sar
Mylosar
NCGC00090851-01
NCGC00090851-02
NCGC00090851-03
NCGC00090851-04
NCGC00090851-08
NCGC00178234-01
NCI-C01569
NINDS_000125
NS-17
NSC 102816
NSC102816
NSC-102816
Pharmion brand OF azacitidine
Pharmion Brand of Azacitidine
pyrimidine antimetabolite: inhibits nucleic acid replication
S1782_Selleck
SAM002264595
SMR000857239
SPBio_000892
Spectrum_001262
SPECTRUM1502111
Spectrum2_000786
Spectrum3_001509
Spectrum4_000922
Spectrum5_001166
ST056940
s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl- (8CI)
TL80073599
U 18496
U-18496
UNII-M801H13NRU
Vidaza
Vidaza (TN)
wr 183027
WR-183027
ZINC03861768
|
|
3 |
|
Antibodies |
|
Phase 1 |
|
|
|
4 |
|
Immunoglobulins, Intravenous |
|
Phase 1 |
|
|
|
5 |
|
Rho(D) Immune Globulin |
|
Phase 1 |
|
|
|
6 |
|
gamma-Globulins |
|
Phase 1 |
|
|
|
7 |
|
Immunologic Factors |
|
Phase 1 |
|
|
|
8 |
|
Immunoglobulins |
|
Phase 1 |
|
|
|
Interventional clinical trials:
(show all 17)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sialic Acid Extended-Release Tablets in Patients With GNE Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM) |
Completed |
NCT02377921 |
Phase 3 |
aceneuramic acid extended-release (Ace-ER);Placebo |
2 |
Phase 3B Open-Label Extension Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With GNE Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM) |
Terminated |
NCT02736188 |
Phase 3 |
Aceneuramic Acid Extended-Release Tablets |
3 |
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy |
Completed |
NCT01517880 |
Phase 2 |
Sialic Acid Extended Release (SA-ER);Placebo |
4 |
An Open-label Phase 2 Extension Study to Evaluate the Long Term Safety and Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets and Sialic Acid-Immediate Release (SA-IR) Capsules in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy |
Completed |
NCT01830972 |
Phase 2 |
SA-ER 500 mg;SA-IR 500 mg |
5 |
An Open-Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy |
Completed |
NCT02346461 |
Phase 2 |
ManNAc;ManNAc |
6 |
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of ManNAc in Subjects With GNE Myopathy |
Not yet recruiting |
NCT04231266 |
Phase 2 |
ManNAc |
7 |
A Phase 2 Open-label Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER) Tablets in GNE Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy (HIBM)) Patients With Severe Ambulatory Impairment |
Terminated |
NCT02731690 |
Phase 2 |
Aceneuramic Acid Extended-Release |
8 |
Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation to Manage or Treat Muscular Dystrophies. |
Unknown status |
NCT00674843 |
Phase 1 |
|
9 |
Pharmacokinetic Study on N-acetylneuraminic Acid in Patients With Distal Myopathy With Rimmed Vacuoles (DMRV) - Hereditary Inclusion Body Myopathy (hIBM) |
Completed |
NCT01236898 |
Phase 1 |
NPC-09 |
10 |
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Single and Repeat Doses of Sialic Acid Extended Release (SA-ER) Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM) |
Completed |
NCT01359319 |
Phase 1 |
Sialic Acid Extended Release (SA-ER) Tablets;Sialic Acid Extended Release (SA-ER) Tables;Sialic Acid Extended Release (SA-ER) Tablets;Sialic Acid Extended Release (SA-ER) Tablets;Sialic Acid Extended Release (SA-ER) Tablets |
11 |
A Phase 1 Randomized, Placebo-Controlled, Double-Blind, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM) |
Completed |
NCT01634750 |
Phase 1 |
ManNAc |
12 |
Pilot Study of the Use of Intravenous Immune Globulin in Hereditary Inclusion Body Myopathy |
Completed |
NCT00195637 |
Phase 1 |
Immune Globulin |
13 |
International Clinical Outcome Study for Dysferlinopathy |
Unknown status |
NCT01676077 |
|
|
14 |
GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM) |
Completed |
NCT01784679 |
|
|
15 |
Family Studies in Neuromuscular Disorders |
Recruiting |
NCT01459302 |
|
|
16 |
International GNE Myopathy Patient Registry (GNE001) |
Recruiting |
NCT04009226 |
|
|
17 |
A Natural History Study of Patients With GNE Myopathy |
Recruiting |
NCT01417533 |
|
|
Cochrane evidence based reviews: miyoshi myopathy
|